Investigational drug · Phase 2
JT002
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Seasonal Allergic Rhinitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "JT002"
First trial start
2025
Feb 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JT002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Seasonal Allergic Rhinitis
Approved drugs for the same conditions: Allergies (allergic rhinitis)
Largest trials
Live from ClinicalTrials.gov: studies naming "JT002" as an intervention, largest first.
- Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in AdultsPivotal-lookingCompleted
Shanghai JunTop Biosciences Co., LTDIndustry
NCT06861101 · 370 participants · Start Feb 24, 2025 · Primary completion May 6, 2025
Drug: JT002 Nasal spray; Placebo · For: Seasonal Allergic Rhinitis
Sites: Beijing, China; Fuzhou, China; Wuwei, China · 44 sites in all
Jeil Pharmaceutical Co., Ltd.Industry
NCT06165965 · 48 participants · Start May 3, 2022 · Primary completion Jun 13, 2022
Drug: SGLT2 inhibitor · For: Healthy Adult
Sites: Gyeonggi-do, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Author Correction: JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders.
Ambrus-Aikelin G, Takeda K, Joetham A, et al. · Sci Rep 2023
- JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders.
Ambrus-Aikelin G, Takeda K, Joetham A, et al. · Sci Rep 2023
Also in development for Seasonal Allergic Rhinitis
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
- SHR-1819Phase 38 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Seasonal Allergic Rhinitis, Moderate to Severe Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
- MG-K10 Humanized Monoclonal AntibodyPhase 34 trials
Shanghai Mabgeek Biotech.Co.Ltd · Atopic Dermatitis, Seasonal Allergic Rhinitis, Chronic Spontaneous Urticaria (CSU)
- TQH2722Phase 33 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Seasonal Allergic Rhinitis, Atopic Dermatitis
- AK139Phase 26 trials
Akeso · Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria
- TQC2938Phase 22 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Chronic Obstructive Pulmonary Disease, Seasonal Allergic Rhinitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.